How Has The Hemato Oncology Testing Market Size Evolved In Recent Years?
The hemato oncology testing market has seen considerable growth due to a variety of factors.
•In recent years, the hemato oncology testing market has undergone swift expansion. The market size is projected to escalate from $3.5 billion in 2024 to $3.96 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.3%.
The notable growth during the historical period is attributed to factors such as the surge in cancer occurrence, the proliferation of awareness and screening programs, increased healthcare spending, the rising trend of personalized medication, and the growing prevalence of blood-related disorders.
What Are The Estimated Market Size And Expected Annual Growth Rates For Global Hemato Oncology Testing Market?
The hemato oncology testing market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the hemato oncology testing market is projected to experience a swift expansion, rising to "$6.83 billion in 2029 with a compound annual growth rate (CAGR) of 14.6%.
The predicted growth during the forecast period is linked to trends in personalized medicine, the integration of artificial intelligence, an increasing elderly population, advancements in genomic research, and the rising demand for early cancer detection. Other significant developments foreseen during this forecast period include advancements in genomic testing technology, the use of liquid biopsy for non-invasive testing, increased industry collaborations and partnerships, regulatory and standardization changes, and technological progress.
What Are The Essential Drivers Behind The Growth Of The Hemato Oncology Testing Market?
The growth of the hemato oncology testing market is anticipated to be fueled by the escalating number of hematologic cancer cases. Hematologic cancers are a type of cancer that begin in the blood, impacting the bone marrow, blood, and lymphatic system, inclusive of conditions like leukemia, lymphoma, and myeloma. The incidence of these diseases can be lowered through early diagnosis, achievable via hemato oncology testing. The American Cancer Society, a US-based voluntary health organization dedicated to cancer eradication, projected that 59,610 Americans will be affected by leukemia, resulting in 23,710 deaths in 2023. Moreover, it predicted that new non-Hodgkin lymphoma patients will number 80,550, leading to 20,180 deaths. Consequently, the growing occurrence of hematologic cancers is driving the hemato oncology market's growth.
How Is The Global Hemato Oncology Testing Market Divided Into Key Segments?
The hemato oncology testing market covered in this report is segmented –
1) By Product And Services: Assay Kits And Reagents, Services
2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma, Other Cancers
3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
4) By End User: Hospitals, Academic And Research Institutes, Other End Users
Subsegments:
1) By Assay Kits And Reagents: PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, ELISA Kits, Antibodies
2) By Services: Testing Services, Consultation Services, Data Analysis Services
Pre-Book The Hemato Oncology Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Hemato Oncology Testing Market?
Dominant businesses in the hemato-oncology testing market are ushering in novel technologies such as next-generation sequencing (NGS) to enhance the precision and velocity of genetic evaluation, provide a comprehensive mapping of blood malignancies, and enable customized treatment plans based on each patient's unique needs. NGS is an advanced DNA sequencing method that expedites and cost-effectively analyzes either the entire genome or specific DNA regions. For instance, in October 2024, NeoGenomics Inc., a US-based innovator in cancer diagnostics and genomic examinations, introduced AML Express, an NGS tool specifically designed for the swift identification of mutations linked to Acute Myeloid Leukemia (AML). This trailblazing diagnostic platform provides high reliability and swift results, assisting oncologists in making expedited, focused treatment choices. AML Express aims to enhance patient prognosis by delivering precise mutation data customized to the genetic outlines of AML.
Who Are the Key Players in the Hemato Oncology Testing Market?
Major companies operating in the hemato oncology testing market include:
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Invivoscribe Inc.
• Qiagen N.V.
• Bio-Rad Laboratories Inc.
• Archerdx Inc.
• ARUP Laboratories Inc.
• Asuragen Inc.
• Adaptive Biotechnologies Corp.
• Cepheid Inc.
• EntroGen Inc.
• CORE Diagnostics Inc.
• Genoptix Inc.
• GenPath Diagnostics
• NeoGenomics Laboratories Inc.
• Siemens AG
• Sysmex Corporation
• Laboratory Corporation of America Holdings
• Agilent Technologies
• Danaher Corporation
• Grifols SA
• Diaorin SpA
• HTG Molecular Diagnostics Inc.
• Admera Health
What are the Regional Insights into the Hemato Oncology Testing Market?
North America was the largest region in the hemato oncology testing market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
